CorriXR
corrixr.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Report
Corrixr Therapeutics Names Nancy Whiting, PharmD, as Board Chair
NEWARK, Del., July 15, 2026--Corrixr Therapeutics, a pre-clinical genetic medicine company targeting lung, head & neck, and esophageal squamous cell carcinomas, today announced the appointment of Nancy Whiting, PharmD, as Chair of the Board of Directors,
Read more
Report
Lung Cancer Patients Take a Hit of Inhaled Gene Therapies in Trials
Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its candidate KB707.
Read more
Report
Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients
Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to
Read more
Report
CorriXR Therapeutics Announces Publication of Additional Preclinical Data Corroborating Ability of NRF2 Knockout to Restore Chemosensitivity in Solid Tumors
Read more
Report
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del., August 19, 2025--CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriX
Read more
Report
4 companies to watch in the accelerating gene editing race
A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.
Read more
Report
Show more news